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Summary
Background Retinoblastoma is the childhood retinal cancer that deﬁ ned tumour-suppressor genes. Previous work 
shows that mutation of both alleles of the RB1 retinoblastoma suppressor gene initiates disease. We aimed to 
characterise non-familial retinoblastoma tumours with no detectable RB1 mutations.
Methods Of 1068 unilateral non-familial retinoblastoma tumours, we compared those with no evidence of RB1 
mutations (RB1+/+) with tumours carrying a mutation in both alleles (RB1–/–). We analysed genomic copy number, RB1 
gene expression and protein function, retinal gene expression, histological features, and clinical data.
Findings No RB1 mutations (RB1+/+) were reported in 29 (2·7%) of 1068 unilateral retinoblastoma tumours. 15 of the 
29 RB1+/+ tumours had high-level MYCN oncogene ampliﬁ cation (28–121 copies; RB1+/+MYCNA), whereas none of 
93 RB1–/– primary tumours tested showed MYCN ampliﬁ cation (p<0·0001). RB1+/+MYCNA tumours expressed 
functional RB1 protein, had fewer overall genomic copy-number changes in genes characteristic of retinoblastoma 
than did RB1–/– tumours, and showed distinct aggressive histological features. MYCN ampliﬁ cation was the sole copy-
number change in one RB1+/+MYCNA retinoblastoma. One additional MYCNA tumour was discovered after the initial 
frequencies were determined, and this is included in further analyses. Median age at diagnosis of the 17 children with 
RB1+/+MYCNA tumours was 4·5 months (IQR 3·5–10), compared with 24 months (15–37) for 79 children with non-
familial unilateral RB1–/– retinoblastoma.
Interpretation Ampliﬁ cation of the MYCN oncogene might initiate retinoblastoma in the presence of non-mutated 
RB1 genes. These unilateral RB1+/+MYCNA retinoblastomas are characterised by distinct histological features, only a 
few of the genomic copy-number changes that are characteristic of retinoblastoma, and very early age of diagnosis.
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Research Foundation, Canadian Retinoblastoma Society, Hyland Foundation, Toronto Netralaya and Doctors Lions 
Clubs, Ontario Ministry of Health and Long Term Care, UK-Essen, and Foundations Avanti-STR and KiKa.
Introduction
Retinoblastoma set the paradigm for tumour-suppressor 
genes, with Knudson’s classic hypothesis predicting that 
two rate-limiting hits initiate this childhood eye cancer.1 
The two hits were later attributed to the retinoblastoma 
gene (RB1).2 40% of children with retinoblastoma have 
bilateral disease. They carry a constitutional RB1 
mutation that predisposes to retinoblastoma; one 
additional hit damages the second RB1 allele and initiates 
retinoblastoma or other cancers later in life. In 70% of 
bilateral tumours, the second hit entails loss of the 
normal allele with duplication of the mutant allele (loss 
of heterozygosity). The other 60% of children with 
retinoblastoma have unilateral non-familial disease. In 
these cases, usually both RB1 alleles are damaged only in 
the developing retina, but 15% carry a heritable con-
stitutional RB1 mutation. Accepted dogma is that 
disruption of both RB1 alleles (RB1–/–) initiates all cases of 
retinoblastoma.2–4
The mutant RB1 allele is identiﬁ able in blood samples of 
95% of bilaterally aﬀ ected patients. Low-level mosaicism 
can account for the remaining 5% of blood samples in 
which no mutation is found.5 Previously, we have 
identiﬁ ed mutations in both RB1 alleles (or promoter 
methylation) in more than 95% of tumours from unilateral 
probands with no known family history.5,6 In 3–4% of 
tumours, we iden tiﬁ ed only one RB1 mutation, and in 2% 
we saw no disruption to RB1. Undetected RB1 mutations 
in fully tested tumours (RB1+/+) might include 
translocations, deep intronic mutations, or alterations in 
unknown RB1 regulatory regions. The possibility that 
some unilateral retinoblastomas with no detectable RB1 
mutations arise by an independent mechanism has, to 
our knowledge, not been investigated before. We aimed to 
characterise unilateral retinoblastomas with non-mutated 
RB1 alleles for other genetic changes.
Methods
Study population
Five clinical laboratories took part in this study: Impact 
Genetics (formerly Retinoblastoma Solutions), Toronto, 
Canada; Institut für Humangenetik, Essen, Germany; 
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Service de Génétique Oncologique, Paris, France; 
Canterbury Health Laboratories, Christchurch, 
New Zealand; and VU University Medical Center Depart-
ment of Clinical Genetics, Amsterdam, Netherlands. We 
obtained tissue samples and clinical data for identiﬁ cation 
of RB1 mutations from children in clinical care at these 
labora tories, and their families. Every laboratory 
contributed both local and international families. We 
obtained research ethics board approval to use 
deidentiﬁ ed data and tissues for clinical analyses, which 
are on ﬁ le at every participating site. Although not 
required, patients from Toronto and Essen provided 
written informed consent.
Procedures
Full details of Methods are provided in the appendix. We 
used standard-of-care analyses that identify 95% of RB1 
(Genbank accession L11910.1) mutant alleles.5–7 
Assessments included DNA sequencing, quantitative 
multiplex PCR (QM-PCR) or multiplex ligation-
dependent probe ampliﬁ cation (MLPA), and RB1 
promoter-methylation testing (appendix pp 2–3). 
To ascertain zygosity of RB1+/+ tumours, we used 
intragenic and closely linked RB1 microsatellite markers 
and single nucleotide poly morphisms (SNPs). We did 
either QM-PCR (Toronto) or MLPA or SNP analyses 
(Amsterdam) to measure genomic copy numbers of ﬁ ve 
genes known to be commonly altered in RB1–/– 
retinoblastomas (KIF14, DEK, E2F3, CDH11, and 
MYCN). We used sub-megabase resolution array 
comparative genomic hybridisation (aCGH) or SNP 
array to assess overall genomic copy numbers and non-
tumour cell contamination (appendix p 3).
We placed three primary RB1+/+MYCNA tumours in 
the same culture conditions that support growth of 
RB1–/– cell lines, and we developed these into cell lines 
(appendix p 4). We stained paraﬃ  n-embedded sections of 
retinoblastomas and adjacent normal retinas for full-
length RB1 protein (antibodies targeted N-terminal and 
C-terminal RB1 protein) and MYCN protein.8 We did 
western blots on RB1+/+MYCNA and RB1–/– primary tumours 
and cell lines, control RB1+/+ human fetal and adult retina, 
and lymphoblastoid and neuroblastoma cell lines 
(appendix pp 3–4). We did western blotting to assess the 
function of RB1 protein, using phospho-speciﬁ c anti-RB1 
and coimmunoprecipitation of RB1 and its major eﬀ ector 
molecule E2F1. We used endpoint reverse transcriptase 
PCR (RT-PCR) or quantitative real-time PCR to measure 
expression of RB1, MYCN, and genes reﬂ ecting the 
proliferative status and retinal derivation of tumours.
Statistical analysis
To assess the likelihood that RB1+/+ tumours originated 
from two undetected RB1 mutations, we did the 
χ² goodness-of-ﬁ t test, using default probabilities of 
p1=0·0025 for RB1+/+ and p2=0·9975 for RB1–/– samples 
(appendix pp 4–5). We established the bimodal 
distribution of MYCN copy number in RB1+/+ tumours 
with a two-tailed t test, using Welch’s adjustment for 
heteroscedasticity. We used the statistical program R 
(version 2.13.2) for these analyses. To compare the 
proportion of RB1+/+ unilateral tumours at every study 
site and frequencies of speciﬁ c genomic copy-number 
changes of tumours with diﬀ erent RB1 statuses, we used 
Fisher’s exact test (appendix p 13).9
We used the t test with Welch’s adjustment to compare 
the total number of bp altered per region between 
RB1+/+MYCNA and RB1–/– tumours (appendix p 5). 
We processed normalised intensity values with the 
circular binary segmentation algorithm, with data ﬁ ltered 
to identify only high quality (greater than three 
conﬁ rmatory probes) and suitably sized (>25 kbp) 
regions of clear diﬀ erential signal relative to normal 
(|mean–signal| >0·1). We ﬁ tted separate terms to groups 
using a general linear model. We used a contrast matrix 
to identify the number of diﬀ erentially abundant probes 
relative to normal sam ples with an empirical Bayes 
moderation of SE and a false-discovery rate adjustment 
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Total 
retinoblastoma 
specimens (n)
RB1⁺/⁺ tumours 
(%)
RB1⁺/⁺MYCNA 
tumours (%)
Canada 441 7 (1·6%) 5 (1·1%)
Germany 400 12 (3·0%) 4 (1·0%)
France 150 5 (3·3%) 2 (1·3%)
New Zealand 30 2 (6·7%) 1 (3·3%)
Netherlands 47 3 (6·4%) 3 (6·4%)
Total 1068 29 (2·7%) 15 (1·4%)
Table 1: Frequency of RB1⁺/⁺ unilateral retinoblastoma at ﬁ ve diagnostic 
laboratories
Figure 1: Copy numbers of genes commonly altered in RB1–/– retinoblastoma
(A) Box plot of genomic copy numbers ascertained by quantitative multiplex PCR for common genes in unilateral 
retinoblastoma, grouped by RB1 mutation status. Specimen T33 is an outlier of the RB1+/– group and shows an 
RB1+/+MYCNA-like proﬁ le. Dashed line represents two copies. (B) Heat map for copy number of proﬁ le genes. 
Red=increased copy number. Blue=decreased copy number. Grey=two copies. White=not tested. Black 
triangles=ﬁ ve RB1+/+MYCNA tumours not included in (A).
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for multiple testing. We did these analyses with the R 
statistical program (version 2.11.1), using the DNAcopy 
(version 1.22.1) and limma (version 3.4.4) packages.
To compare age of diagnosis between groups, we did 
pairwise comparisons with the Wilcoxon rank-sum test. 
We estimated the likelihood of children having 
RB1+/+MYCNA tumours at diﬀ erent ages of diagnosis. 
We analysed ages at diagnosis versus proportion not yet 
diagnosed to assess the minimum number of events for 
tumour initiation (appendix p 5). To ascertain if ages at 
diagnosis were from a one-hit or two-hit distribution,1 we 
estimated the parameter k in the equation ln S=–kT 
(in which S is the proportion of cases not yet diagnosed 
and T is age at diagnosis) through a simple linear no-
intercept regres sion analysis. We regressed the empirical 
values of S on age at diagnosis,1 assuming an exponential 
distribution (one-hit), and in the equation ln S=–kT², 
assuming a Weibull distribution with shape parameter of 
two (two-hit). To compare the relative ﬁ t of these data to 
the two assumptions, we plotted data points for RB1–/– 
and RB1+/+MYCNA cases and the best-ﬁ tting curves. We 
used SAS version 9.3 (TS level 1M1) for analyses of 
number of events to initiate retinoblastoma.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all 
data in the study; the corresponding author (BLG) had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
During clinical work in Toronto, we found seven (1·6%) 
of 441 unilateral retinoblastoma tumours with no RB1 
mutations, no promoter methylation, and no RB1 loss of 
heterozygosity (RB1+/+). We used QM-PCR to measure, in 
RB1+/+ tumours, copy numbers of genes at 6p, 1q, 16q, 
and 2p that are characteristically gained or lost in RB1–/– 
retinoblastoma tumours.10 Unexpectedly, ﬁ ve of seven 
RB1+/+ tumours showed striking ampliﬁ cation of the 
MYCN oncogene (MYCNA). To validate this observation, 
we collaborated with RB1 clinical laboratories in 
Germany, France, and New Zealand. After initial studies, 
we learnt that the Amsterdam group had independently 
discovered three RB1+/+MYCNA tumours. We combined 
our data on 1068 primary unilateral non-familial 
retinoblastoma tumours after statistical analysis showed 
that frequencies did not diﬀ er by much (p=0·08) between 
the ﬁ ve laboratories (table 1). 
The standard sensitivity for ﬁ nding the RB1 mutation 
in blood samples of bilaterally aﬀ ected individuals is 
greater than 95%.5–7 The probability of ﬁ nding no RB1 
mutations in a tumour with no RB1 loss of hetero zygosity 
is equivalent to the probability of missing two 
independent RB1 mutations in one sample (0·05×0·05) 
or 0·25%. By combining our data on 1068 unilateral 
non-familial tumours, we identiﬁ ed 29 (2·7%) RB1+/+ 
tumours, tenfold more than expected (p<0·0001; table 1). 
Subsequently, a new patient was predicted clinically and 
pathologically to have an RB1+/+MYCNA tumour (T101), 
conﬁ rmed by MYCN copy number; thus, 30 RB1+/+ 
retinoblastomas were included in further analyses 
(appendix p 6).
To characterise copy numbers of genes commonly 
gained or lost in retinoblastomas,10 we used QM-PCR 
(Toronto) or MLPA and SNP (Amsterdam) analyses. 
MYCN copy number was raised in 27 (90%) of 30 RB1+/+ 
versus 60 (65%) of 93 RB1–/– retinoblastomas (p<0·0001; 
appendix pp 6–12). None of the 93 RB1–/– primary tumours 
showed more than ten MYCN copies. By comparison, 
16 (53%) of 30 RB1+/+ tumours showed high-level MYCN 
ampliﬁ cation (28–121 copies of MYCN; p<0·0001; ﬁ gure 1; 
appendix pp 6–12, 30). The remaining 14 RB1+/+ tumours 
showed between two and ten MYCN copies. For ten 
Figure 2: Genomic copy number alterations
(A) aCGH of 12 RB1+/+MYCNA (including T33; red), 12 RB1+/+ (blue), 13 RB1+/– (green), and 11 RB1–/– (purple) tumours. 
Gains are shown to the right of the chromosome, losses to the left. Minimum commonly gained or lost regions in 
RB1–/– tumours are boxed. T33 showed a loss of most of 13q. *Normally occurring copy number variations. (B) The 
minimum amplicon of 513 kbp is deﬁ ned by two MYCNA tumours (pink band). MYCN copy number (by QM-PCR) is 
shown in red italics. aCGH individual probes are denoted as green bars. aCGH=sub-megabase resolution array 
comparative genomic hybridisation. QM-PCR=quantitative multiplex PCR.
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children with RB1+/+MYCNA tumours, DNA from available 
blood samples showed two MYCN copies.
The 16 RB1+/+ MYCNA tumours showed a lower 
frequency of copy-number changes in four other genes 
characteristic of retinoblastoma, compared with RB1–/– 
retinoblastoma: gain of oncogenes KIF14 (three of 
16 [19%] vs 55 of 89 [62%]; p=0·002), DEK (one of 16 [6%] 
vs 50 of 87 [57%]; p=0·0002), and E2F3 (one of 16 [6%] vs 
52 of 90 [58%]; p=0·0002); and loss of tumour-suppressor 
gene CDH11 (two of 16 [13%] vs 50 of 90 [56%]; p=0·002; 
ﬁ gure 1; appendix pp 6–13). SNP analysis indicated that 
the level of non-tumour cell contamination in 
RB1+/+MYCNA tumours was low and similar to RB1–/– 
tumours (appendix p 3).
To probe for other genomic gains or losses, we studied 
DNA from 48 unilateral retinoblastomas by aCGH11 
(11 RB1+/+MYCNA, 12 RB1+/+, 14 RB1–/–, and 11 RB1+/– in 
samples from Canada, Germany, France, and New Zealand) 
and three RB1+/+MYCNA tumours by SNP analysis 
(Netherlands; ﬁ gure 2A; appendix pp 6–12, 14–28, 33). 
None of the RB1+/+MYCNA retino blastomas showed any 
evidence of copy-number changes or translocations12 at the 
RB1 locus. Except for MYCN copy number, aCGH 
(ﬁ gure 2A) conﬁ rmed a reduced frequency in RB1+/+MYCNA 
retino blastomas of the speciﬁ c genomic copy-number 
changes characteristic of RB1–/– retinoblastomas (ﬁ gure 1; 
appendix p 13).10 Also, RB1+/+MYCNA retino blastomas 
showed signiﬁ  cantly fewer altered bp and aCGH clones 
overall than did RB1–/– retinoblastomas (p=0·033; ﬁ gure 2A; 
appendix pp 31, 14–28).
We used aCGH11 or SNP analysis3 to study MYCN 
ampliﬁ cations in 14 RB1+/+MYCNA retinoblastomas, one 
RB1+/– tumour (T33, with 73 MYCN copies), and one 
RB1–/– primary tumour (RB381, with 9·2 copies of 
MYCN). MYCN amplicons were narrow, spanning 
1·1–6·3 Mbp and encompassing MYCN (appendix 
pp 14–28, 32–33). The only copy-number change detected 
in one RB1+/+MYCNA retinoblastoma (E4) was 48 copies of 
2p24·2–24·3, en compassing MYCN. The minimum 
common amplicon deﬁ ned by retinoblastomas 
T33 (RB1+/–) and P2 (RB1+/+) spanned 513 kbp containing 
only MYCN (ﬁ gure 2B). RB1+/+MYCNA retinoblastomas 
T5 and P2 also deﬁ ned a minimal common amplicon 
including only MYCN. Of the 35 remaining unilateral 
tumours tested by aCGH (ten RB1–/–, 13 RB1–/+, and 
12 RB1+/+), 24 showed no gain or loss at MYCN, and 
11 had moderate gain spanning a broad region of at least 
28 Mbp of chromosome 2p, too large to meet the 
deﬁ nition of ampliﬁ cation.13
Three of 14 RB1+/+MYCNA tumours showed 17q21·3-qter 
or 17q24·3-qter gain; two showed 11q loss. Both regions 
are commonly altered in neuroblastoma,14,15 but changes 
are rare in RB1–/– retinoblastoma.16,17 Other changes in 
RB1+/+MYCNA retinoblastomas not typically seen in RB1–/– 
retinoblastoma were gains at 14q and 18q and losses 
at 11p (ﬁ gure 2A; appendix pp 14–20, 33).
Retinoblastoma T33 (RB1+/–) showed high-level MYCN 
ampliﬁ cation and loss of one copy of most of 13q, 
including RB1; we suspect that ampliﬁ cation of MYCN 
initiated proliferation, followed by 13q deletion. Since T33 
showed several characteristics of RB1+/+MYCNA tumours, 
we included T33 with MYCNA retinoblastomas in clinical 
analyses (ﬁ gure 2, ﬁ gure 3A; appendix pp 32, 34).
RB1+/+MYCNA retinoblastomas and retinal cell types 
(ganglion cells, speciﬁ c inner nuclear cells, and cone 
photoreceptors)18 expressed functional RB1 protein and 
showed nuclear staining for C-terminal (ﬁ gure 4A; 
appendix p 34) and N-terminal (data not shown) epitopes, 
whereas RB1–/– and RB1+/– tumours were negative or 
stained weakly, depending on their RB1 mutations. 
Western blots and immunoprecipitation in three 
RB1+/+MYCNA cell lines (A3, RB522, and T101) derived 
from RB1+/+MYCNA primary retinoblastomas showed 
functional, nuclear, full-length RB1 protein (appendix 
pp 34–35), normally hypophosphorylated and hyper-
phosphorylated (ﬁ gure 4B; appendix p 35), and bound to 
E2F1 (ﬁ gure 4C), which is the major target of RB1 protein 
and controls the cell cycle.19 Full-length 2·8 kbp RB1 
transcripts were detected by endpoint and real-time 
Figure 3: Clinical features of children with retinoblastomas
(A) Age at diagnosis of children with retinoblastomas. Children with RB1+/+MYCNA retinoblastomas were 
signiﬁ cantly younger than those with RB1–/– tumours (p<0·0001, Wilcoxon rank sum test). (B) Knudson one-hit and 
two-hit plots for children with RB1–/– or RB1+/+MYCNA tumours, comparing proportion not yet diagnosed with age at 
diagnosis, using birth as a surrogate for initiation. Scatterplot does not distinguish children of identical ages.
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RT-PCR in three RB1+/+MYCNA primary retinoblastomas 
for which mRNA was available (appendix pp 29, 36). 
By contrast, four primary RB1–/– retinoblastomas expressed 
low RB1 transcript levels relative to fetal and adult retina.
RB1+/+MYCNA primary retinoblastomas (ﬁ gure 4A) and 
three derived cell lines (data not shown) stained strongly 
for MYCN protein. MYCN and KI67 transcripts 
(indicative of proliferation) were found at low levels in 
adult retina, at higher levels in fetal retina and in RB1–/– 
retinoblastomas without MYCN ampliﬁ cation, and at 
very high levels in primary RB1+/+MYCNA retinoblastoma 
and RB1–/– cell lines with MYCN ampliﬁ cation (appendix 
pp 29, 36). RB1+/+MYCNA tumours showed reduced 
expression of the oncogene KIF14,10 by contrast with 
healthy fetal retina and RB1–/– primary retinoblastomas, 
which overexpressed KIF14 (appendix pp 29, 36).
RB1+/+MYCNA tumours expressed embryonic cell markers 
consistent with a retinal origin. mRNA of cone cell marker 
X-arrestin20 and CRX (a marker of retinal and pineal lineage 
tumours, which is strongly expressed in RB1–/– 
retinoblastoma but not in neuroblastoma)21 were expressed 
in fetal retina, human adult retina, and RB1+/+MYCNA and 
RB1–/– primary retinoblastomas (appendix p 36).
Children with RB1+/+MYCNA retinoblastomas were much 
younger at diagnosis than were those with uni lateral RB1–/– 
retinoblastomas. Median age at diagnosis of 17 children 
with RB1+/+MYCNA tumours (n=16) and RB1+/–MYCNA 
(T33; n=1) was 4·5 months (IQR 3·5–10), which diﬀ ered 
signiﬁ cantly from that for 79 children with unilateral 
sporadic RB1–/– tumours (24 months [15–37]; p<0·0001) 
and 14 children with RB1+/+ retino blastomas (21·5 months 
[16–45]; p<0·0001; ﬁ gure 3A; appendix p 9). Age at 
diagnosis did not diﬀ er between patients with RB1–/– and 
RB1+/+ tumours without MYCN ampliﬁ cation (p=0·94). We 
estimated that 18% of children diagnosed with non-familial 
unilateral retinoblastoma at age 6 months or younger will 
have RB1+/+MYCNA retino blastoma (appendix p 5).
Analysis of age at diagnosis versus proportion not yet 
diagnosed led Knudson to propose his two-hit model for 
initiation of retinoblastoma.1 Our data for 79 unilaterally 
aﬀ ected RB1–/– patients accorded with Knudson’s model 
and ﬁ t a two-hit curve, representative of two independent 
mutational events in a tumour-suppressor gene (ﬁ gure 3B). 
Similar analysis of RB1+/+MYCNA tumours was 
inconclusive: although datapoints for 12 children 
diagnosed before age 10 months approximated the 
calculated one-hit curve, ages for older children deviated 
(ﬁ gure 3B).
RB1+/+MYCNA tumours had distinctive histological 
features, comprising undiﬀ erentiated cells with large, 
prominent, multiple nucleoli, and necrosis, apoptosis, 
and little calciﬁ cation. These features are similar to those 
seen in other MYCNA embryonic tumours, such as 
neuroblastoma22 (ﬁ gure 5A; appendix p 34). Flexner-
Wintersteiner rosettes23 and nuclear moulding, which are 
characteristic of prototypic RB1–/– retinoblastoma 
(ﬁ gure 5B), were absent.
Clinically, RB1+/+MYCNA retinoblastomas were large and 
invasive, in view of the young age of aﬀ ected children 
(ﬁ gure 5C; appendix p 37). One RB1+/+MYCNA 
retinoblastoma had already invaded the optic nerve past the 
cribriform plate at age 11 months, a feature of aggressive 
disease.24,25 However, with follow-up of 2–25 years, the 
children with RB1+/+MYCNA tumours had no further 
evidence of retinoblastoma after removal of their aﬀ ected 
eye and none developed retinoblastoma in their other eye.
Discussion
Knudson’s analysis of retinoblastoma was fundamental 
to the idea that normal genes suppress cancer1 and led to 
identiﬁ cation of the RB1 tumour-suppressor gene,2 
BA
C
MYCN
Total
RB1
pRB1
M
ur
in
e t
hy
m
us
W
ER
I-R
b1
In
pu
t
Y7
9
RB
24
7
RB
10
21
T1
01
RB
52
2
E2F1
Immunoprecipitate
IgG RB1 E2F1
RB
1+
/+
 M
YC
N
A
RB
1+
/+
 M
YC
N
A
RB
1–
/–
RB
1–
/–
RB
1–
/–
RB
1+
/+
 M
YC
N
A
RB
1+
/+
RB
1+
/–
T25
INL
INL
INL
T
T T
T
INL
T25
T76 T76
RB1
60 µm
60 µm 60 µm
60 µm
In
pu
t Immunoprecipitate
IgG RB1 E2F1
RB1
E2F1
RB
52
2
A3
In
pu
t
RB1
E2F1
RB1
E2F1RB
1+
/+
M
YC
N
A
Y7
9
RB1
E2F1
W
ER
I-R
b1 RB1
E2F1
H
SC
93
RB1
E2F1
RB1
E2F1
T1
01
Sp
ec
im
en
Specimen
Sp
ec
im
en
Figure 4: Expression of RB1 and MYCN
(A) Staining of adjacent retinal tissue and RB1+/+MYCNA or RB1 mutant retinoblastoma for MYCN protein and RB1 
protein (C-terminus antibody). T=tumour. INL=inner nuclear layer retina. (B) Western blots with anti-RB1 that 
recognises both hypophosphorylated and hyperphosphorylated RB1 protein (total RB1), phospho-RB1 (Ser795) 
antibody (pRB1), and anti-E2F1. (C) Cell lysates immunoprecipitated with antibodies against mouse IgG (negative 
control), RB1 protein, and E2F1, and western blots done with antibodies to RB1 and E2F.
Articles
332 www.thelancet.com/oncology   Vol 14   April 2013
mutation of which is widely assumed to initiate all 
retinoblastoma (panel). In this report, we have described 
a previously unrecognised form of retinoblastoma that 
has no evidence of RB1 muta tions, displays functional 
protein, and is probably initiated by ampliﬁ cation of the 
MYCN oncogene.
Of 1068 unilateral non-familial retinoblastomas, 
we identiﬁ ed a distinct RB1+/+MYCNA subtype that 
constituted 1·4% of the sample (n=15). At least two 
previously described tumours might also be RB1+/+MYCNA 
retinoblastomas,26 although RB1 genetic status was not 
deﬁ ned. Despite the low frequency of RB1+/+MYCNA 
retinoblastoma, this tumour subtype was discovered and 
characterised independently in two laboratories (Toronto 
and Amsterdam), using diﬀ erent cohorts and technologies. 
Statistical analyses show that although rare, RB1+/+MYCNA 
retinoblastomas aﬀ ect an im portant subset of patients.
We also identiﬁ ed 14 RB1+/+ retinoblastomas without 
MYCN ampliﬁ cation. aCGH showed genomic gains 
and losses that were distinct from either RB1–/– or 
RB1+/+MYCNA retinoblastomas, but we did not have 
enough RB1+/+ tumour samples for gene expression 
or protein studies. In particular, these RB1+/+ retino-
blastomas showed frequent gain of 19p and q, 17p and q, 
2p, and the telomeric end of 9q. The RB1+/+ group seems 
heterogeneous and merits further study.
Our work highlights how molecular diagnostics can 
identify novel malignant diseases that elude histopatho-
logical recognition. Although RB1+/+MYCNA retino-
blastomas have not been recognised previously as a distinct 
subtype, they resemble large nucleolar neuro blastomas 
with MYCN ampliﬁ cation and poor out come.22 Similar to 
MYCN-ampliﬁ ed neuroblastomas,15 RB1+/+MYCNA tumours 
have less complex alterations of genomic copy number 
than do tumours without MYCN ampliﬁ cation, suggesting 
that MYCNA could be the important driver of malignancy. 
However, the early age of diagnosis of RB1+/+MYCNA 
tumours allows less time to accumulate genomic 
alterations. Although whole-genome sequencing has 
suggested that point mutations (other than in the RB1 
gene) are few in RB1–/– retino blastoma,27 loss of RB1 
induces mitotic changes and lagging chromosomes,28 
leading to genomic instability. Loss of RB1 in 
retinoblastoma and premalignant retinoma8,17 is associated 
with speciﬁ c changes in DNA copy number, which are less 
frequent in RB1+/+MYCNA retinoblastomas.
Are RB1+/+MYCNA tumours truly retinoblastomas? 
These malignant subtypes arise in and express markers 
of embryonic retina, meeting the deﬁ nition of retino-
blastoma as a blast-cell tumour arising from the 
retina.20,21,29 We showed intact RB1 genes in primary 
RB1+/+MYCNA retinoblastomas with strong nuclear RB1 
antibody staining. Three RB1+/+MYCNA cell lines 
expressed full-length RB1 mRNA and inactive hyper-
phosphorylated and active hypophosphorylated RB1 
protein that coimmunoprecipitated with E2F1, indicating 
normal functional RB1 protein.19 The possibility that non-
malignant cell contamination could be masking RB1 
mutations in RB1+/+MYCNA tumours is ruled out because 
three RB1+/+MYCNA cell lines grew rapidly from the 
primary tumours, unlike RB1–/– retinoblastoma, and 
maintained the RB1+/+MYCNA genotype of the primary 
tumours.
Although next-generation DNA sequencing is a 
powerful discovery technique, its clinical application has 
not yet achieved sensitivity to match RB1 mutation 
detection technologies. If an RB1 mutation were 
identiﬁ ed by the next-generation enhanced read depth 
approach, that variant would represent convergent 
evolution to knockout RB1 protein with cancer 
progression, common in many cancers, rather than an 
initiating RB1 mutation. Based on the cell-line genotypes, 
the MYCN ampliﬁ cation would still be the event common 
to all cells and, thereby, the probable initiating event.
The very early presentation of RB1+/+MYCNA retino-
blastomas, absence of RB1 mutations, functional RB1 
protein, and high MYCN ampliﬁ cation in a genome with a 
Figure 5: Clinical features of retinoblastomas
(A) Fundus image (upper panel) of an RB1+/+MYCNA unilateral tumour (T101), extending from optic nerve (single 
arrow) to anterior border of retina (double arrows) in a 4-month-old child with characteristic calciﬁ cation on 
ultrasound (middle panel) and round nuclei with prominent large multiple nucleoli on histopathology (lower 
panel). (B) RB1–/– tumour (T37) showing classic Flexner-Wintersteiner rosettes and nuclear moulding (haemoxylin 
and eosin staining). (C) RB1+/+MYCNA retinoblastoma in an 11-month-old child (A2) with extraocular extension 
into the optic nerve (triple arrows; haemoxylin and eosin staining). (D) 3·5-month-old child with a small, heritable, 
RB1–/– retinoblastoma present in the inner nuclear layer of the retina on optical coherence tomography (OCT).
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fairly stable copy number suggests that these tumours 
arise by somatic MYCN oncogene ampliﬁ cation in a retinal 
progenitor cell. This idea is supported by the ﬁ nding of 
one RB1+/+MYCNA tumour in which MYCN ampliﬁ cation 
was the only identiﬁ ed genomic copy-number change. 
RB1+/+MYCNA retinoblastomas are already large in very 
young children so they probably are initiated earlier in 
retinal development than are RB1–/– retinoblastomas. 
In children with an RB1 mutation of equivalent age, 
tumours are usually much smaller (ﬁ gure 5D). The 
method by which MYCN ampliﬁ cation is initiated, and 
whether MYCN ampliﬁ cation alone is suﬃ  cient to initiate 
retinoblastoma, remains to be shown formally.
In retinal development, the MYCN protein can sup port 
cell division without activation of the E2F family of 
transcription factors; presumably, unregu lated MYCN 
expression associated with high-level gene ampliﬁ cation in 
RB1+/+MYCNA tumours promotes cell division by indirect 
inactivation of RB1 protein.30 The relative genomic stability 
of RB1+/+MYCNA retino blastomas could result in less 
resistance to treatment, which is seen in RB1–/– 
retinoblastoma associated with progressive genomic 
rearrangements. Our preliminary MYCN knock-down 
experiments resulted in rapid death of RB1+/+MYCNA cell 
lines (data not shown). We predict that, worldwide, infants 
younger than 1 year24 with extraocular retinoblastoma 
could have RB1+/+MYCNA tumours and might beneﬁ t from 
anti-MYCN treatment.31 This idea accords with an 
anecdotal observation by one of us (BLG) during review of 
retinoblastoma pathology slides in Kenya, of RB1+/+MYCNA 
histological ﬁ ndings in an orbital recurrence, later 
conﬁ rmed to have 40 MYCN copies.
The young age at diagnosis of unilateral retinoblastoma 
is interpreted frequently as an indication of heritable 
disease and is cited as a reason to try to cure the cancer 
without enucleation. However, attempts to salvage an eye 
with a large RB1+/+MYCNA retinoblastoma could be 
dangerous. In our study, no further retinoblastoma was 
identiﬁ ed after prompt removal of the unilateral aﬀ ected 
eye, with no adverse outcomes. The young patients with 
RB1+/+MYCNA tumours in our study had large aggressive 
tumours, including invasion into the optic nerve 
(ﬁ gure 5C). At similar young ages, usual hereditary 
RB1–/– tumours are much smaller, detected only by active 
surveillance (ﬁ gure 5D). Although we predict that 18% of 
children diagnosed with non-familial unilateral retino-
blastoma at age 6 months or younger will have 
RB1+/+MYCNA retinoblastoma (appendix p 5), if tumour 
size is also considered, RB1+/+MYCNA tumours might be 
clinically predictable, facilitating prompt removal of 
these eyes with good outcomes for children.
Standard care for unilateral non-familial retino-
blastoma is identiﬁ cation of the RB1 mutant alleles in the 
tumour and examination of blood to ascertain whether 
either mutant allele is germline. When no RB1 mutation 
is detected in a retinoblastoma tumour, establishing the 
MYCN copy number could assist ongoing care. Diagnosis 
of RB1+/+MYCNA retinoblastoma strongly suggests non-
hereditary disease, with normal population risks for 
retinoblastomas in the other eye and for other cancers 
throughout life, and no familial risks.
Our ﬁ ndings challenge the longstanding dogma that 
all retinoblastomas are initiated by RB1 gene mutations. 
RB1+/+MYCNA retinoblastoma diﬀ ers from classic retino-
blastoma in terms of both genetics and clinical charac-
teristics (table 2), with immediate relevance to patients.
Contributors
DER recognised the initial connection between MYCN ampliﬁ cation and 
RB1 mutation status, did the literature search and QM-PCR analysis, 
supervised RB1 mutation analysis, coordinated collaborations with the 
other sites, and made a major contribution to preparation of the report. 
BMM recognised the RB1 and MYCN mutation status of the Amsterdam 
samples and did MLPA and SNP array analysis, western blots, and 
coimmunoprecipitation. JYK did aCGH and analysed aCGH data. 
SY analysed aCGH data and the MYCNA alignment and did 
immunohistochemistry and RT-PCR. SP did the literature search and 
RT-PCR and immunohistochemistry. BLT did the literature search and 
RNA expression studies. NLP-L did the literature search and statistical 
analyses, grew cell lines, and contributed to preparation of ﬁ gures and 
the report. CS did immunohistochemistry. HD and TWC did the 
Classic RB1/ Novel RB1⁺/⁺MYCNA
RB1 status –/– +/+
RB1 protein expression Rare Full-length, nuclear, 
phosphorylated, binds E2F1
Speciﬁ c and general genomic gains and losses Common Uncommon
MYCN copy number 2–9 copies, wide region 28–121 copies, narrow amplicon
MYCN mRNA expression Moderate High
Histological characteristics Rosettes Multiple nucleoli and blast cells
Median (IQR) age at diagnosis (months) 24 (15–37) 4·5 (3·5–10)
Table 2: Diﬀ erences between classic RB1/ tumours and novel RB1⁺/⁺MYCNA unilateral non-familial 
retinoblastoma
Panel: Research in context
Systematic review
We systematically searched PubMed with the terms: “retinoblastoma”, “initiation”, and 
“genetics”; “retinoblastoma tumour genetics”; “retinoblastoma development”; and 
“retinoblastoma initiation”. We reviewed retrieved publications with a main focus on 
genetic initiation and development of human retinoblastoma. We identiﬁ ed no data to 
challenge Knudson’s 1971 conclusion that two rate-limiting events,1 later shown to be loss 
of both RB1 gene alleles,2–5,7 are essential, but not necessarily suﬃ  cient, for development of 
retinoblastoma. We found no data to suggest other forms of retinoblastoma.
Interpretation
With our collaborative studies, we identiﬁ ed a previously unrecognised disease: 
retinoblastoma with normal RB1 genes, apparently driven by MYCN oncogene 
ampliﬁ cation. This new form of retinoblastoma has immediate clinical implications for 
patients. RB1⁺/⁺MYCNA retinoblastomas are diagnosed by molecular study of the tumour 
after removal of the eye of very young children with unilateral non-familial disease. 
Children with RB1⁺/⁺MYCNA retinoblastoma and their relatives are predicted to be at 
normal population risk for other cancers. Attempts to salvage the eye on the assumption 
of heritable disease in young children could incur high treatment morbidity and failure to 
cure these aggressive oncogene-driven retinoblastomas.
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literature search, assisted with data analysis and ideas for the discussion, 
and contributed to preparation of ﬁ gures and the report. RP did 
statistical and bioinformatic analyses on aCGH data. CM did statistical 
analyses. RG discovered and characterised the ﬁ rst tumour with MYCN 
ampliﬁ cation and normal RB1 protein (RB522; now RB1+/+MYCNA) and 
provided the cell line and western blot showing multiple bands of RB1 
protein. ZJ and EZ did western blots speciﬁ c to phosphorylated RB1 
protein. KP and ACM provided and interpreted clinical data and images. 
CH and AR did RB1 mutation analysis and provided clinical data. WH 
recognised and characterised the histological features of RB1+/+MYCNA 
retinoblastomas and prepared digital images for publication. WLL 
supervised JYK and the aCGH experiments. PCB did detailed analyses of 
aCGH data and statistical analyses throughout the project and 
supervised RP. DL did the literature search and RB1 mutation analysis 
and contributed to preparation of ﬁ gures and development of ideas. JCD 
coordinated the Amsterdam study, recognised the RB1 and MYCN 
mutation status of the Amsterdam samples, and supervised BMM. BLG 
supervised the overall study, did the literature search, provided guidance 
on all parts of the project, and contributed to preparation of ﬁ gures and 
the report. All authors contributed ideas and helped to write the report.
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